Ignyta Inc (RXDX) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP lowered its stake in Ignyta Inc (NASDAQ:RXDX) by 26.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 18,400 shares of the biopharmaceutical company’s stock after selling 6,500 shares during the period. Two Sigma Advisers LP’s holdings in Ignyta were worth $491,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. QS Investors LLC bought a new stake in shares of Ignyta in the 4th quarter worth about $117,000. Amalgamated Bank acquired a new position in shares of Ignyta in the 4th quarter valued at about $213,000. IFP Advisors Inc boosted its holdings in shares of Ignyta by 62.4% in the 4th quarter. IFP Advisors Inc now owns 12,743 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 4,898 shares during the period. Teacher Retirement System of Texas acquired a new position in shares of Ignyta in the 4th quarter valued at about $357,000. Finally, DLD Asset Management LP acquired a new position in shares of Ignyta in the 4th quarter valued at about $374,000. 72.28% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

Ignyta stock opened at $26.98 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 6.07 and a quick ratio of 6.07. Ignyta Inc has a 52-week low of $5.80 and a 52-week high of $27.10.

Several research firms have recently commented on RXDX. Jefferies Group lowered shares of Ignyta from a “buy” rating to a “hold” rating and set a $27.00 price target for the company. in a report on Thursday, December 28th. Zacks Investment Research lowered shares of Ignyta from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th. Cantor Fitzgerald set a $23.00 price target on shares of Ignyta and gave the company a “buy” rating in a report on Friday, December 22nd. Ladenburg Thalmann lowered shares of Ignyta from a “buy” rating to a “neutral” rating in a report on Tuesday, December 26th. Finally, ValuEngine raised shares of Ignyta from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Seven investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $27.00.

COPYRIGHT VIOLATION WARNING: This news story was posted by Week Herald and is the property of of Week Herald. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://weekherald.com/2018/04/21/ignyta-inc-rxdx-shares-sold-by-two-sigma-advisers-lp.html.

Ignyta Profile

Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.

Want to see what other hedge funds are holding RXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ignyta Inc (NASDAQ:RXDX).

Institutional Ownership by Quarter for Ignyta (NASDAQ:RXDX)

Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply